Introduction
============

Gastric cancer (GC) is the fourth most common diagnosed cancer worldwide and ranks second as the cause of cancer-related death ([@b1-or-41-05-3089]). The etiology of GC is complicated and remains an active focus of research. In addition to environmental risk factors, genetics may play a role in the development and progression of the disease ([@b2-or-41-05-3089],[@b3-or-41-05-3089]). Many studies have explored the genetic mechanisms underlying GC, including the direct effects of protein-coding genes, e.g. *TP53, HOXB5, TGF-β, SK* and *THBS1* ([@b4-or-41-05-3089]--[@b8-or-41-05-3089]), and the indirect effects of non-coding RNAs (ncRNAs), e.g., let-7a, miR-21 and SNGH8 ([@b9-or-41-05-3089],[@b10-or-41-05-3089]).

Recently, a new and largest class ([@b11-or-41-05-3089]) of non-coding small RNAs, i.e., piwi-interacting RNAs (piRNAs), which interact with a subset of Argonaute proteins related to Piwi, has become a focus of intense research ([@b12-or-41-05-3089]). piRNAs are non-coding RNAs with 24--32 nucleotides (nt). Although structurally only slightly longer than microRNAs (miRNAs; 19--25 nt), piRNAs are different in expression pattern and quantity, as well as in genomic organization ([@b13-or-41-05-3089]--[@b15-or-41-05-3089]). piRNAs are initially discovered in germline cells. Germline and certain 'lower' eukaryotic organisms are 'non-aging' biological systems that display an indefinite capacity for renewal and a lifespan-stable genome integrity, and are potentially immortal ([@b16-or-41-05-3089]). piRNA is a shared feature of all non-aging biological systems ([@b16-or-41-05-3089]). Interestingly, cancer stem cells also display an indefinite capacity of renewal and proliferation and are potentially immortal ([@b16-or-41-05-3089]). An increasing number of studies have shown aberrant piRNA expression as a molecular signature across multiple tumor types ([@b17-or-41-05-3089],[@b18-or-41-05-3089]), including renal cancer ([@b19-or-41-05-3089]), breast cancer ([@b14-or-41-05-3089],[@b20-or-41-05-3089]), multiple myeloma ([@b21-or-41-05-3089]), and hepatocellular carcinoma ([@b22-or-41-05-3089]), suggesting that piRNAs may be involved in the pathogenesis of cancer ([@b12-or-41-05-3089]). For instance, upregulated expression of piR-36743, piR-20365, piR-20485, piR-4987 and piR-932 was observed in breast cancer as compared to matched non-cancerous tissues ([@b23-or-41-05-3089],[@b24-or-41-05-3089]); and the expression of piRABC was increased in bladder cancer, as compared to their corresponding adjacent non-cancerous tissues ([@b25-or-41-05-3089]). These findings also suggest that piRNAs are a shared feature of this non-aging biological system, cancers. In an earlier work, we reported associations between piRNAs and Alzheimer\'s disease ([@b26-or-41-05-3089]), a clinical condition strongly related to aging. Cancers are just opposite to the aging diseases in renewal and proliferation capacity, which also suggests a potential role of piRNAs in cancers. Recently, a study reported that 156 piRNAs were significantly deregulated in GC ([@b27-or-41-05-3089]).

The sequences of piRNAs primarily complement the transposable elements (TEs). The most widely recognized and well-characterized function of piRNAs is to suppress the activities of TEs at genomic and epigenetic levels ([@b17-or-41-05-3089]). TEs are capable of moving from one genomic locus to another, thereby causing insertional mutations ([@b28-or-41-05-3089],[@b29-or-41-05-3089]). There are two major classes of TEs: RNA transposons (or retrotransposons) and DNA transposons, as distinguished by their mechanism of transposition ([@b28-or-41-05-3089]). Retrotransposons include long terminal repeats (LTRs), long interspersed nuclear element (LINE), and short interspersed nuclear elements (SINE). As the primary determinants of genomic instability ([@b16-or-41-05-3089]), TEs exert pathological effects via controlling the transcription of neighboring genes ([@b30-or-41-05-3089]). The downregulation of piRNA pathways would increase the repeats of retrotransposon and cause DNA damage, which represents the primary genetic determinant of aging. The upregulation of piRNAs suppresses the activity of TEs, which protects against TE-mediated mutagenesis, maintains genomic integrity, and self-renewal and proliferation capacity, and thereby preserves the non-aging features of cancer cells ([@b16-or-41-05-3089]). Additionally, piRNA may also be involved in a TE-independent mechanism in cancer risk; that is, it may regulate the transcription of certain key cancer-related genes via non-TE sequence complementarity ([@b16-or-41-05-3089],[@b31-or-41-05-3089]) or modulation of chromatin organization ([@b16-or-41-05-3089]). In the present study, we aimed to identify the piRNAs in association with GC across the transcriptome using a piRNA profile. Further, we explored whether these GC-associated piRNAs are expressed in other tissues, and whether their nearest protein-coding genes were expressed in the stomach and perhaps even related to gastrointestinal cancers.

For many years investigators have scanned the whole genome to search for risk DNA variants for GC. In reviewing all published genome-wide association studies (GWASs) and whole genome/exome sequencing studies of GC, we found that only three variants were genome-wide significant in association with GC and replicated across at least two independent studies at single-point level. The three variants are rs4072037 at *MUC1* (on Chr1) ([@b32-or-41-05-3089]--[@b35-or-41-05-3089]), rs13361707 at *PRKAA1* (on Chr5) ([@b34-or-41-05-3089],[@b36-or-41-05-3089]) and rs2294008 at *PSCA* (on Chr8) ([@b34-or-41-05-3089],[@b35-or-41-05-3089]). Numerous candidate gene studies supported these GWAS findings. However, the mechanisms underlying these SNP-GC associations are not clear. Here we examined whether the GC-related piRNAs might mediate the SNP-GC associations, in order to explore the potential roles of piRNAs in the pathogenesis of GC.

Materials and methods
=====================

### Subjects

The primary cohort including eight gastric cancer(GC) tissues and adjacent normal tissues extracted from eight male patients (aged 49--79 years old) was examined in a piRNA microarray study. The clinical characteristics of the GC patients are shown in [Table I](#tI-or-41-05-3089){ref-type="table"}. Fresh gastric tissue samples were collected from GC patients who underwent surgical resection at the Fujian Provincial Cancer Hospital. A second cohort of 20 paired GC and adjacent normal tissues extracted from 15 male and 5 female patients (aged 32--78 years old) was also obtained from the same hospital for validating the findings obtained from the first cohort. A third cohort of 181 paired GC and adjacent normal tissues extracted from 134 male and 47 female patients (aged 28--73 years old) from the same hospital was tested for piwi protein expression in the stomach. These cohorts were recruited between June 2015 and February 2018. None of the patients received chemotherapy before surgery and tissues were obtained immediately after tumor resection. Medical diagnoses were confirmed histopathologically, and clinical pathological data were obtained. Histological classification of GC was assessed according to the Lauren\'s criteria ([@b37-or-41-05-3089]). Patients were staged according to the 7th Edition of the TNM staging system of the American Joint Commission on Cancer (AJCC) ([@b38-or-41-05-3089]). The study was approved by the Research Ethics Committee of the Fujian Provincial Cancer Hospital, China. Informed consents from all patients were obtained prior to the study. All experiments were performed in accordance with relevant guidelines and regulations.

### piRNA microarray experiment

The ArrayStar HG19 piRNA array was used to profile piRNA expression in humans (ArrayStar; Agilent Technologies, Santa Clara, CA, USA). This array contains probes for 23,677 piRNAs obtained from the National Center for Biotechnology Information (NCBI) database (<https://www.ncbi.nlm.nih.gov/nuccore/?term=piRNA>) and landmark publications ([@b15-or-41-05-3089],[@b39-or-41-05-3089]). Human piRNAs were mapped to the HG19 genome sequence using UCSC Blat (<https://genome.ucsc.edu/cgi-bin/hgBlat?command=start>). Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to manufacturer\'s instructions. Sample labeling was performed using an RNA ligase method ([@b40-or-41-05-3089]). The labeled samples were hybridized onto Arraystar Human piRNA Array in Agilent\'s SureHyb Hybridization Chambers according to manufacturer\'s standard protocols (Agilent Technologies). After slides were scanned, data were extracted using Agilent Feature Extraction software. Raw signal intensities were normalized in quantiles by GeneSpring GX v11.5.1 (Agilent Technologies), and low intensity piRNAs were filtered. Agilent Feature Extraction software (version 11.0.1.1) was used to analyze the acquired array images ([@b40-or-41-05-3089]). Normalized intensity values were then log~2~-transformed.

### Quality assessment of piRNA data after normalization and filtering

We used a Box Plot to visualize the distributions of a dataset. We compared the distributions of the intensities from all samples and showed that. after normalization, the distributions of log2-ratios among the samples were nearly the same ([Fig. S1](#SD1-or-41-05-3089){ref-type="supplementary-material"}). We used a Scatter Plot to assess the piRNA expression variation (or reproducibility) between arrays ([Fig. S2](#SD1-or-41-05-3089){ref-type="supplementary-material"}). This plot showed good reproducibility of our array data.

The distribution of all of the observed P-values from the differential expression analysis (see below) was fitted to the expected P-values using a QQ plot. A transcriptomic inflation factor (λ) was computed from these P-values and defined as the ratio of the median of the empirically observed distribution of the test statistic to the expected median, thus quantifying the extent of the bulk inflation and the excess false positive rate. It was computed for the genomic control analysis to reflect the maximum possible inflation factor if the associations were affected by population stratification. A λ with a departure of less than 0.1 from a value of 1.0 is considered an indicator of very good quality and robust associations.

### Differential expression analysis

The normalized and log2-transformed intensities were compared between GC cases and normal controls by paired Student\'s t-test. Fold-changes (FCs) between the two groups were calculated by 'normalized intensity values in Group 1 divided by Group 2'. Significantly differentially expressed piRNAs, which were associated with GC, were identified through Volcano Plot filtering (FC≥1.5 and P≤0.05). The expression level of each piRNA in each individual was also shown in a Heat Map, and clustered using Hierarchical clustering analysis to show the relationships among the expression levels of samples.

### Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) experiment

We selected some candidate piRNAs from the top list of the significantly differentially expressed piRNAs to be examined by qPCR in an independent cohort (20 cases vs. 20 controls), in order to control the quality of microarray experiment and validate piRNA-GC associations as derived from the differential expression analysis on the array data. The selection criteria for these candidate piRNAs include that: i) their expression in gastric cancer tissues should have top intensities \>1,500 in the array data; ii) their expression in gastric cancer tissues should be higher than adjacent tissues with top FCs ≥2.4; and iii) they are located at or close to those genes that have been reported by literature to be cancer-related. After this selection, only two piRNAs, i.e., DQ579739 and DQ600515, were included ([Table II](#tII-or-41-05-3089){ref-type="table"}). Both piRNAs were abundantly expressed in gastric cancer tissues \[log2(normalized intensity) \>10\], and differentially expressed between cases and controls in the array data (P\<0.05).

To measure the piRNA expression levels, a miScript Reverse Transcription (RT) kit (Guangzhou RiboBio Co., Ltd., Guangzhou, China) was used to generate cDNA, according to the manufacturer\'s instructions ([@b40-or-41-05-3089]). Next, qRT-PCR was performed in a 20 µl reaction volume with the following reagents (Guangzhou RiboBio Co., Ltd): SYBR-Green Mix \[10 µl of SYBR-Green I mix, 0.5 µl of miDETECTATrack™ miRNA forward and reverse primers (10 µM), and 2 µl of cDNA template\] on the ABI7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with the following protocol: 95°C for 3 min and 40 cycles of 95°C for 10 sec, 60°C for 20 sec, and 70°C for 1 sec.

Using the comparative 2^−ΔΔCq^ method ([@b41-or-41-05-3089]) and an example gastric carcinoma sample as a calibrator, the relative expression levels in all gastric carcinoma samples and adjacent non-tumorous stomach tissues were quantified. Hs_5S_miScript expression was used to normalize piRNA expression levels between different samples.

### Risk gene expression in the stomach

The primary function of piRNAs is to suppress TEs that will then control the transcription of nearby genes. piRNAs affect the phenotypes primarily via TE suppression. The target TEs that are potentially regulated by the risk piRNAs were searched from UCSC Genome Browser (<http://genome.ucsc.edu>; genome assembly, hg19; track, RepeatMasker). We hypothesized that, without prior knowledge, the nearest genes to which the sequences of the piRNAs are complementary should be the most likely targets for TE regulation ([@b30-or-41-05-3089],[@b31-or-41-05-3089]). These genes were thus carefully examined in this study. The relationship between the genes and GC or related cancers was searched in PubMed ([Table SI](#SD1-or-41-05-3089){ref-type="supplementary-material"}). The mRNA expression of these genes in stomach was examined in two independent cohorts without cancers, including an American cohort (n=262) ([@b42-or-41-05-3089]), and a UK European cohort (n=176) ([@b43-or-41-05-3089]). The density of the proteins encoded by these genes was also examined in stomach of a Germany cohort ([@b44-or-41-05-3089]). If a gene had a normalized intensity \>36 (by RNA microarray), a TPM \>1 (by RNA-Seq) or a value \>10 ppm (by mass spectrometry-based proteomics microarray) in the expression levels in human stomach of these three cohorts or had been reported to be expressed in human stomach in the literature, it was marked 'E: Expressed' ([Table SI](#SD1-or-41-05-3089){ref-type="supplementary-material"}). The detailed demographic data of these three cohorts and the expression values of the top four genes are shown in [Table SII](#SD1-or-41-05-3089){ref-type="supplementary-material"}. Overall, the genes expressed in stomach are more likely to be implicated in stomach diseases than non-stomach genes. Of note, the expression of these genes was not examined in the primary cohort, which represented a limitation of the study.

### The piwi protein expression in the stomach

piRNAs regulate cellular activities by interacting with piwi proteins to form a complex ([@b17-or-41-05-3089]). The golden criterion to confirm the presence of piRNAs is the existence of piwi proteins in the same tissue. To test the expression of piwi in stomach, the mRNA and protein expression of piwi, including PIWIL1, PIWIL2, PIWIL3 and PIWIL4 was examined in the above three independent cohorts, including the American ([@b42-or-41-05-3089]), UK European ([@b43-or-41-05-3089]) and Germany cohorts ([@b44-or-41-05-3089]). The most abundant piwi protein (here, PIWIL4) was further tested in our own samples (181 GC and 181 adjacent tissues), using microarray and immunohistochemistry (IHC) technologies (see Supplementary Methods).

### Expression quantitative trait locus (eQTL) analysis

The 3 genome-wide significant (P\<5×10^−8^) risk variants for GC were genotyped in the primary cohort of 16 subjects (8 cases and 8 controls). The associations between these risk variants and GC have been replicated by at least two independent genome-wide association studies (GWASs) ([Table SIII](#SD1-or-41-05-3089){ref-type="supplementary-material"}). To examine whether the GC-associated piRNA expression was controlled by any of these GC-risk SNPs, we performed eQTL analysis. Usually, a piRNA controlled by DNA variants is more likely to be functional than those uncontrolled. Associations between the genotypes and expression level of each GC-associated piRNA were analyzed using t-test or one-way ANOVA. This correlation is assumed to potentially underlie SNP-disease associations. The design of the whole study was based on a regulation pathway as illustrated in [Fig. S3](#SD1-or-41-05-3089){ref-type="supplementary-material"}.

Results
=======

### Differential expression of piRNAs between cases and controls ([Figs. S4, 1 and 2](#SD1-or-41-05-3089){ref-type="supplementary-material"}, and [Tables II](#tII-or-41-05-3089){ref-type="table"} and [SI](#SD1-or-41-05-3089){ref-type="supplementary-material"})

Among the 23,677 piRNAs, 8,759 (37.0%) were detected in the human stomach. The expression levels of these 8,759 piRNAs in each individual are shown in the HeatMap ([Fig. S4](#SD1-or-41-05-3089){ref-type="supplementary-material"}). A total of 8,759 P-values were obtained from the 8,759 differential expression analyses. The observed and expected P-values fitted very well (see QQ plot in [Fig. 1](#f1-or-41-05-3089){ref-type="fig"}). The λ was 1.07, indicating that the array data were of high quality, the differential expression analysis was robust, and transcriptome-wide inflation and excess false positive rates in the differential expression analysis were very low. That is, the associations were less likely to be affected by population stratification.

Fifty piRNAs with length of 26--32 nt were nominally differentially expressed between cases and controls (FC\>2.0; P\<0.05; without Bonferroni correction) ([Fig. 2](#f2-or-41-05-3089){ref-type="fig"}; [Table SI](#SD1-or-41-05-3089){ref-type="supplementary-material"}). The mean log2-transformed normalized intensity of these 50 piRNAs was 7.46±3.34 (3.21--13.79) in GC cases, and 8.02±2.97 (2.75--12.74) in controls. Among the 50 risk/protective piRNAs, 17 were upregulated and 33 were downregulated in cases in contrast to controls. Among the 50 piRNAs, 41 risk piRNAs potentially targeted at 41 TEs, including 1 DNA transposon, 20 SINEs, 12 LINEs and 8 LTRs ([Table SI](#SD1-or-41-05-3089){ref-type="supplementary-material"}). Thirty piRNAs mapped within 23 protein-coding genes, 13 mapped close to 11 protein-coding genes, and the other 7 mapped close to 5 ncRNAs. Twenty-two of these 34 (23+11) protein-coding genes (64.7%) were expressed in stomach, and 18 piRNAs were located in 15 piRNA clusters, 10 of which were located in intergenic regions. Seventeen (77.2%) of these 22 protein-coding stomach genes have been related to various human cancers in the literature, including gastric cancer ([@b6-or-41-05-3089]--[@b8-or-41-05-3089]), colon cancer ([@b45-or-41-05-3089]--[@b50-or-41-05-3089]), colorectal cancer ([@b51-or-41-05-3089]--[@b53-or-41-05-3089]), pancreatic cancer ([@b54-or-41-05-3089]--[@b56-or-41-05-3089]), hepatocellular carcinoma ([@b57-or-41-05-3089]--[@b59-or-41-05-3089]) and bladder cancer ([@b60-or-41-05-3089]) ([Table SI](#SD1-or-41-05-3089){ref-type="supplementary-material"}).

Thirteen piRNAs had log2-transformed normalized intensities \>10 (i.e., \>1,000 before transformation). The top five piRNAs with highest intensities in cases were DQ588779 at *SKI* (SKI proto-oncogene) (on chr1), DQ595533 at *COLQ* (on chr3), and DQ571813, DQ590386 and DQ595534 at *VAC14* (on chr16) ([Table II](#tII-or-41-05-3089){ref-type="table"}).

Two piRNAs, i.e., DQ590922 and DQ572848 close to TLE4 (on chr9), were expressed with \>2.5 FCs in cases compared to controls. Nine piRNAs were expressed with \>3.5 FCs in controls compared to cases; and the top five of them were DQ574148, DQ574145 and DQ574146 at *IGLL1* (on chr22), DQ598137 at *NUTM2A* (on chr10), and DQ583043 close to *LOC100652909* (on chr19) ([Table II](#tII-or-41-05-3089){ref-type="table"}).

Ten piRNAs were significantly differentially expressed between cases and controls with P\<0.01. The four most significant ones with higher FCs in cases were DQ570687 at *RPL3* (on chr22), DQ580689 at *NBPF3* (on chr1), DQ575884 close to *EPCAM* (on chr2) and DQ572848 close to *TLE4* (on chr9) (0.012≤P≤0.024). The five most significant ones with lower FCs in cases were all intergenic, including DQ577345 close to *LOC400685* (chr19), DQ587262 close to *LOC100507584* (chr6), DQ594511 close to *LOC100287846* (chr8), and DQ575557 and DQ594440 close to *IQSEC1* (chr3) (0.003≤*P*≤0.004) ([Table II](#tII-or-41-05-3089){ref-type="table"}).

Some genes within or near which the GC-associated piRNAs are located have been reported to be associated with gastrointestinal cancers. They are *CXCL17, EPCAM, EED, TLE4, SKI, RPL3* and *HOXB5* ([Table SI](#SD1-or-41-05-3089){ref-type="supplementary-material"}).

### qPCR validation

In a second cohort of 20 patients with gastric cancer, qPCR analysis on two piRNAs selected from the top list verified the quality of microarray experiment and validated the piRNA-GC associations in the primary cohort. DQ579739 and DQ600515 expression in the second cohort was concordant with the microarray data in the primary cohort. Notably, DQ579739 (P=0.001) and DQ600515 (P=0.005) expression in GC in the second cohort was significantly higher than in adjacent tissues ([Fig. 3](#f3-or-41-05-3089){ref-type="fig"}), consistent with the differential analysis on the array data in the primary cohort ([Fig. 2](#f2-or-41-05-3089){ref-type="fig"}) and in the same direction of association (i.e., upregulated).

### Gene expression in the stomach

Among the 50 GC-associated piRNAs, 43 were located within or close to 34 protein-coding genes. Twenty-two (64.7%) of the 34 genes within or close to which the 26 GC-associated piRNAs (60.5%) were located were expressed in human stomach ([Table SI](#SD1-or-41-05-3089){ref-type="supplementary-material"}). The top four risk genes most abundant in stomach were *CXCL17, EPCAM, RPL3* and *RPS8* ([Table SII](#SD1-or-41-05-3089){ref-type="supplementary-material"}).

### piRNA expression is correlated with SNPs

eQTL analysis showed that many GC-associated piRNAs were nominally correlated with the genome-wide significant risk SNPs (1.6×10^−4^≤P\<0.05; [Table III](#tIII-or-41-05-3089){ref-type="table"}). After Bonferroni correction (α=0.001), the correlations of rs4072037 at *MUC1* with DQ595533, DQ590386, DQ595534 and DQ571813 in the whole sample (N+T) (P=3.6×10^−4^, 2.6×10^−4^, 1.6×10^−4^ and 2.6×10^−4^, respectively) and with DQ573237 in control group (P=9.3×10^−4^) remained significant. The results are also illustrated in [Fig. S3](#SD1-or-41-05-3089){ref-type="supplementary-material"}.

### Piwi proteins are expressed in the stomach

Among the four piwi proteins, PIWIL4 was most abundant in stomach in the American cohort (TPM=3.9; GTEx). It was also expressed in our stomach samples of both 80 GC and 127 adjacent tissues (all expression scores ≥2^+^). There was significant difference in the weighted expression scores between GC and adjacent tissues (P=2.3×10^−7^; [Table IV](#tIV-or-41-05-3089){ref-type="table"}; [Fig. S5](#SD1-or-41-05-3089){ref-type="supplementary-material"}).

Discussion
==========

In the present study, we found that piRNAs are abundant in the human stomach, with 50 of them significantly associated with GC. Many GC-associated piRNAs were correlated with the genome-wide significant risk SNPs for GC and potentially regulated the transcription of cancer-related genes in the stomach via TE-suppression or TE-independent mechanisms. These findings support the proposition that piRNAs might play a role in determining GC risk.

These 50 piRNAs might impact GC risk via targeting the TEs and then regulating the expression of the proximate protein-coding genes, by sequence complementarity. Of them, 17 piRNAs, were upregulated in GC. This upregulation might suppress the activity of TEs, which maintains the self-renewal and proliferation capacity of cancer cells. The other 33 piRNAs were significantly downregulated in GC. This downregulation would increase the repeats of retrotransposon and cause DNA damage. We illustrate these potential mechanisms underlying the pathogenicity of piRNAs in [Fig. S3](#SD1-or-41-05-3089){ref-type="supplementary-material"}.

In the present study, 8,759 piRNAs were detected in the human stomach. Across the transcriptome, an average of 5% of the piRNAs mapped within the protein-coding genes ([@b61-or-41-05-3089]). However, in the present study, of the 50 differentially expressed piRNAs, 30 (60%) mapped within protein-coding genes, suggesting a strong relationship between these piRNAs and GC. Among the 34 protein-coding genes where the GC-associated piRNAs are located, 50% were expressed in stomach and associated with cancers, again in support of a strong relationship between the piRNAs and GC. Thus, the GC-associated piRNAs contribute to the pathogenesis of GC possibly via regulating their nearest genes based on sequence complementarity ([@b31-or-41-05-3089]).

Two piRNAs, i.e., DQ579739 and DQ588779, are particularly worthy of attention ([@b1-or-41-05-3089]). In our study, DQ579739 expression in GC was higher than in adjacent tissues in both microarray and qPCR validation data across two independent cohorts. The sequence of DQ579739 is complementary to AluSc8, a SINE-type TE, within the *CXCL17* gene. *CXCL17* mRNA was the most abundant in human stomach among all protein-coding genes examined in our study. As a novel acid CXC chemokine, CXCL17 is significantly upregulated in colon cancer ([@b45-or-41-05-3089]), hepatocellular carcinoma ([@b57-or-41-05-3089]), pancreatic carcinogenesis ([@b56-or-41-05-3089]) and lung macrophages ([@b62-or-41-05-3089]), and is associated with carcinogenesis, tumor proliferation, tumor progression ([@b63-or-41-05-3089]), and angiogenesis ([@b64-or-41-05-3089],[@b65-or-41-05-3089]). CXCL17 might act as a chemokine that accelerates tumor progression. The changes in individual piRNA level could influence both auto-regulatory gene expression and the expression of the gene to which the piRNA is complementary ([@b66-or-41-05-3089]). Our finding suggests that this piRNA may be involved in GC development by regulating its host gene and its interacting proteins via AluSc8 ([@b2-or-41-05-3089]). Among all piRNAs examined, the most abundant one in human stomach is DQ588779 at *SKI* (SKI proto-oncogene) (on chr1). This SKI proto-oncogene encodes the nuclear proto-oncogene protein homolog of avian sarcoma viral (v-ski) oncogene. It is expressed abundantly in the stomach, and has been associated with many types of cancers including GC ([@b6-or-41-05-3089],[@b7-or-41-05-3089]). DQ588779 might play important roles in the development of GC by targeting AluSz6, a SINE-type TE, which may regulate the expression of stomach *SKI* gene.

Many GC-associated piRNAs were nominally correlated with the genome-wide significant risk SNPs, suggesting that these GC-associated piRNAs may be biologically functional. Several piRNAs complementary to *COLQ, SAYSD1* and *VAC14* were significantly correlated with rs4072037 on *MUC1*, suggesting a potential *trans*-acting regulation that may underlie SNP-GC associations.

To conclude, piRNAs are abundant in the human stomach and may play important roles in the pathogenesis of gastric cancer, and underlie the SNP-cancer associations as have been identified by GWASs. Overall, the current findings support piRNAs as potential biomarkers for GC diagnosis and prognosis. It is warranted to replicate these findings in larger sample in future work.
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###### 

Pathological features of the subjects with gastric carcinoma.

  Parameters          Discovery samples (n) (for sequencing)   Validation samples (n) (for qPCR)
  ------------------- ---------------------------------------- -----------------------------------
  Sex                                                          
    Male              8                                        15
    Female            0                                          5
  Age (years)                                                  
    \<60              4                                          9
    ≥60               4                                        11
  Location                                                     
    EGJ               4                                          6
    Non-EGJ           4                                        14
  Depth of invasion                                            
    \<T2              0                                          3
    ≥T2               8                                        17
  Lauren\'s type                                               
    Intestinal-type   4                                          6
    Diffuse-type      4                                        14
  Tumor size (cm)                                              
    \<5               4                                        10
    ≥5                4                                        10
  TNM stage                                                    
    I+II              3                                          6
    III+IV            5                                        14
  LN metastasis                                                
    Absent            2                                          6
    Present           6                                        14

n, sample size; EGJ, esophagogastric junction; T2, tumor invades the muscularis propria; TNM, Tumor Node Metastasis; LN, lymph node.

###### 

Top piRNAs significantly differentially expressed between the cases and controls.

                                                                              Normalized intensity            Cancer vs. control                 
  ---------------------------------------------------------------------- ---- ---------------------- -------- -------------------- ----- ------- -------------------
  *With top intensities in cancer (intensities \>1,500)*                                                                                         
  DQ588779^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                29   chr1                   14,194   6,844                2.1   0.037   *SKI*
  DQ595533^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                29   chr3                   13,314   6,148                2.2   0.035   *COLQ*
  DQ571813                                                               31   chr16                  12,123   5,710                2.1   0.046   *VAC14*
  DQ590386                                                               29   chr16                  11,953   5,766                2.1   0.046   *VAC14*
  DQ595534                                                               30   chr16                  11,307   5,429                2.1   0.038   *VAC14*
  DQ600670^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                30   chr11                  4,410    1,805                2.4   0.032   *EED*
  DQ600515^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                29   chr1                   4,071    1,668                2.4   0.041   *ATAD3B*
  DQ580665^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                26   chr7                   2,349    5,133                2.2   0.041   *POLR2J*
  DQ579739^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                30   chr19                  1,844    774                  2.4   0.029   *CXCL17*
  DQ578739                                                               31   chr2                   1,709    3,422                2.0   0.007   to *LOC100507334*
  DQ583443                                                               30   chr9                   1,582    3,683                2.3   0.015   *FAM225A*
  *With top FC between cases and controls (FC≥2.4)*                                                                                              
  DQ590922^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                29   chr9                   32       10                   3.1   0.036   to *TLE4*
  DQ572848^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                30   chr9                   22       8                    2.7   0.024   to *TLE4*
  DQ600670^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                30   chr11                  4,410    1,805                2.4   0.032   *EED*
  DQ600515^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                29   chr1                   4,071    1,668                2.4   0.041   *ATAD3B*
  DQ579739^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                30   chr19                  1,844    774                  2.4   0.029   *CXCL17*
  DQ571419                                                               28   chr1                   1,443    605                  2.4   0.032   *RPS8*
  *With top FC ↓ between cases and controls (FC≥3.8)*                                                                                            
  DQ574148                                                               30   chr22                  25       110                  4.4   0.012   *IGLL1*
  DQ583043                                                               30   chr19                  32       135                  4.2   0.015   to *LOC100652909*
  DQ574145                                                               30   chr22                  18       75                   4.2   0.01    *IGLL1*
  DQ574146                                                               30   chr22                  49       197                  4.1   0.012   *IGLL1*
  DQ598137                                                               28   chr10                  15       58                   4.0   0.017   *NUTM2A*
  DQ570015                                                               30   chr15                  429      1,642                3.8   0.036   *GOLGA8A*
  DQ574147                                                               31   chr22                  55       208                  3.8   0.010   *IGLL1*
  *With lowest P-values between cases and controls and FC ↑ (P≤0.025)*                                                                           
  DQ570687^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                28   chr22                  910      448                  2.0   0.012   *RPL3*
  DQ580689                                                               28   chr1                   180      90                   2.0   0.016   *NBPF3*
  DQ575884^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                32   chr2                   1,393    691                  2.0   0.017   to *EPCAM*
  DQ572848^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                30   chr9                   22       8                    2.7   0.024   to *TLE4*
  *With lowest P-values between cases and controls and FC ↓ (P≤0.005)*                                                                           
  DQ577345                                                               31   chr19                  383      969                  2.5   0.003   to *LOC400685*
  DQ587262                                                               31   chr6                   97       233                  2.4   0.003   to *LOC100507584*
  DQ575557                                                               29   chr3                   25       83                   3.4   0.003   to *IQSEC1*
  DQ594511                                                               29   chr8                   22       45                   2.0   0.004   to *LOC100287846*
  DQ594440                                                               31   chr3                   60       164                  2.7   0.004   to *IQSEC1*
  DQ576821                                                               28   chr19                  28       77                   2.7   0.004   *ZNF490*
  DQ570858                                                               31   chr15                  30       106                  3.5   0.005   *HERC2P7*
  *With locations at or close to cancer-related genes*                                                                                           
  DQ600515^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                29   chr1                   4,071    1,668                2.4   0.041   *ATAD3B*
  DQ594797                                                               26   chr2                   14       7                    2.1   0.042   to *TEKT4*
  DQ580529                                                               30   chr22                  13       30                   2.3   0.022   to *WBP2NL*
  DQ579739^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                30   chr19                  1,844    774                  2.4   0.029   *CXCL17*
  DQ570687^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                28   chr22                  910      448                  2.0   0.012   *RPL3*
  DQ600670^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                30   chr11                  4,410    1,805                2.4   0.032   *EED*
  DQ590922^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                29   chr9                   32       10                   3.1   0.036   to *TLE4*
  DQ595533^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                29   chr3                   13,314   6,148                2.2   0.035   *COLQ*
  DQ588779^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                29   chr1                   14,194   6,844                2.1   0.037   *SKI*
  DQ588880                                                               30   chr17                  30       67                   2.2   0.032   to *HOXB5*
  DQ580665^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                26   chr7                   2,349    5,133                2.2   0.041   *POLR2J*
  DQ590827                                                               30   chr16                  179      367                  2.0   0.037   *DHODH*
  DQ575884^[a](#tfn3-or-41-05-3089){ref-type="table-fn"}^                32   chr2                   1,393    691                  2.0   0.017   to *EPCAM*
  DQ580779                                                               28   chr9                   61       184                  3.0   0.035   *TMOD1*
  DQ600254                                                               29   chr14                  144      354                  2.5   0.027   *PNMA1*

chr, chromosome; ↑, upregulated; ↓, downregulated. FC, fold-change; 'to', proximate to.

Appears at least twice in this table. P-value from t-test.

###### 

The risk piRNAs correlated with the genome-wide significant replicated risk SNPs.

                                         Chr1: *MUC1* rs4072037   Chr5: *PRKAA1* rs13361707   Chr8: *PSCA* rs2294008                                   
  ---------- ------- ------------------- ------------------------ --------------------------- ------------------------ ------- ------- ------- ------- -------
  DQ575884   chr2    to *EPCAM*          0.026                    0.048                       0.006                    0.044           0.023           
  DQ578739   chr2    to *LOC100507334*                            0.038                                                                                
  DQ571556   chr2    to *SPATA31C1*      0.027                                                                                                         
  DQ595533   chr3    *COLQ*              0.003                    0.023                       **3.6×10**^−4^           0.033           0.005           
  DQ593293   chr5    to *C5orf52*        0.018                                                                                                         
  DQ573237   chr6    *SAYSD1*            **9.3×10**^−4^           0.039                       0.005                    0.016   0.035   0.003           
  DQ580665   chr7    *POLR2J*            0.044                                                0.039                    0.025                           
  DQ583443   chr9    *FAM225A*           0.042                                                                                                         
  DQ571073   chr12   to *CLLU1*                                   0.039                                                                                
  DQ600254   chr14   *PNMA1*             0.008                    0.045                       0.002                    0.032           0.010           
  DQ572562   chr15   *DNM1P46*                                                                0.016                                                    
  DQ590386   chr16   *VAC14*             0.003                    0.022                       **2.6×10**^−4^           0.032           0.004           
  DQ595534   chr16   *VAC14*             0.002                    0.015                       **1.6×10**^−4^           0.026           0.003           
  DQ571813   chr16   *VAC14*             0.002                    0.025                       **2.6×10**^−4^           0.024           0.004           
  DQ577343   chr19   to *LOC400685*      0.002                                                0.023                                                    
  DQ577344   chr19   to *LOC400685*      0.003                                                0.015                                                    
  DQ577345   chr19   to *LOC400685*      0.005                                                0.013                                                    
  DQ583043   chr19   to *LOC100652909*                                                                                                         0.029   
  DQ574146   chr22   *IGLL1*                                                                                                                           0.045
  DQ574147   chr22   *IGLL1*                                                                                                                           0.042
  DQ580529   chr22   to *WBP2NL*         0.004                                                                                                         

SNP, single nucleotide polymorphism; N, controls; T, cases; 'to', proximate to. Correlations with P\<α=0.001 (=0.05/50 piRNAs) are in bold print.

###### 

Piwi protein expression in 181 gastric cancer and adjacent tissues.

           Weighted expression scores                    
  -------- ---------------------------- ---- ------ ---- ------------
  Cancer   49                           52     57   23   
  Normal   21                           33   110    17   2.3×10^−7^

Weighted expression scores: -, scores 0--1; 1^+^, scores 1--2; 2^+^, scores 3--4; 3^+^, scores 6--12 (see detailed scoring in Supplementary Methods).

[^1]: Contributed equally
